ClinicalTrials.gg
CompletedNCT00930683MEDI-546Updated May 8, 2012

A Study to Evaluate Safety and Tolerability of Multiple Doses of MEDI-546 in Adult Subjects With Scleroderma

A Phase 1 interventional study of MEDI-546 and MEDI-546 in Scleroderma, sponsored by MedImmune LLC. Completed at 11 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-05-08.

Sponsored by MedImmune LLC (part of AstraZeneca) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
34
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 153 studies in Scleroderma, Diffuse with a site in United States — 29 open to participants now, 39 under way, 5 of them phase 3. Scleroderma, Diffuse · United States.

Enrollment
54th of 120
34 · median 29
Started
2009
with 5 others
Phase 1
23 of 153
6 open now
Registered
38th of 153
by date

Among the 153 studies in Scleroderma, Diffuse with a site in United States, this one is the 54th largest by enrollment of the 120 interventional ones that give a count, is one of 6 that started in 2009, is one of 23 in phase 1, and was the 38th registered.

Scleroderma, Diffuse

310 studies on the registry are indexed under Scleroderma, Diffuse; 76 are open to participants now.

Browse Scleroderma, Diffuse studies →

Open to participants now

29 of the 153 studies in Scleroderma, Diffuse with a site in United States are open now. Recruiting first, the newest first:

24 more — sign in →

All 29 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 55 Scleroderma, Diffuse studies recruiting now, 28 (51%) set no upper age limit and 20 (36%) stop at 75 or younger; 10 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 153 studies in Scleroderma, Diffuse with a site in United States, or all of them as a file.
02

Study summary

To evaluate the safety and tolerability of a multiple-dosed drug (MEDI-546) in adults with scleroderma.

Read the detailed description

The primary objective of this study is to evaluate the safety and tolerability of single and multiple IV doses of MEDI-546 in adult subjects with scleroderma who have skin thickening in an area suitable for repeat biopsy.

03

Conditions studied

  • Scleroderma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects ≥ 18 years of age at the time of the first dose of MEDI-546;
  • Written and HIPAA authorization (applies to covered entities in the US only) obtained from the subject or subject's legal representative;
  • Must fulfill the American Rheumatism Association (American College of Rheumatology) preliminary classification criteria for systemic sclerosis;
  • Has at least moderate skin thickening (score of at least 2 by modified Rodnan Total Skin Score [mRTSS]) in at least one area suitable for repeat , such as arms, legs, or trunk;
  • Women, unless surgically sterile (including tubal ligation) or at least 2 years , must use an effective method of avoiding pregnancy (including oral, injectable, transdermal, or implanted , intrauterine device, diaphragm with spermicide, cervical cap, abstinence, and sterile sexual partner) in addition to the use of condoms (male or female condoms with spermicide) from signing of the informed consent through the end of the study. Cessation of birth control after this point should be discussed with a responsible physician. Men, unless surgically sterile, must likewise practice 2 effective methods of birth control (condom with spermicide or abstinence) and must use such precautions from Study Day 0 through the end of the study;
  • Ability to complete the study period, including follow-up period through a maximum of Study Day 105; and
  • Willing to forego other forms of experimental treatment during study.

Exclusion criteria

Exclusion Criteria:

  • History of allergy or reaction to any component of the MEDI-546 formulation;
  • Forced vital capacity (FVC) \< 60% predicted, diffusing capacity for carbon monoxide (DLCO) \< 40% predicted, pulmonary hypertension requiring treatment with endothelin receptor antagonists or prostacyclin analogues, scleroderma renal crisis within the last year, or medically significant malabsorption;
  • Have received the following medications within 28 days before entry:

    • Cyclophosphamide at any dose
    • Systemic cyclosporine at any dose
    • Thalidomide at any dose
    • Hydroxychloroquine > 600 mg/day
    • Mycophenolate mofetil > 3 g/day
    • Methotrexate > 25 mg/week
    • Azathioprine > 3 mg/kg/day;
  • Have received leflunomide > 20 mg/day within 6 months before entry;
  • Have received fluctuating doses of the following within 28 days before entry:

    • Antimalarials
    • Mycophenolate mofetil
    • Methotrexate
    • Leflunomide
    • Azathioprine;
  • Have received prednisone > 20 mg/day or in fluctuating doses within 14 days before entry;
  • Have received fluctuating doses of nonsteroidal anti-inflammatory drugs (NSAIDs) within 14 days before entry;
  • Treatment with any drug therapy within 28 days before entry into the study, B cell-depleting therapies within 12 months before entry, or biologic therapies within 30 days or 5 half-lives of the biologic agent, whichever is longer, before entry into the study;
  • In the investigator's opinion, evidence of active infection, including ongoing, chronic infection, within 28 days before entry;
  • A history of severe viral infection as judged by the investigators, including severe infections of either cytomegalovirus (CMV) or the herpes family such as disseminated herpes, herpes encephalitis, ophthalmic herpes;
  • Herpes zoster infection within 3 months before entry;
  • Evidence of infection with or C virus, or (HIV)-1 or HIV-2, or active infection with hepatitis A, as determined by results of testing at screening;
  • Vaccination with live attenuated viruses within 28 days before entry;
  • Pregnancy (women, unless surgically sterile or at least 2 years , must have a negative serum pregnancy test within 28 days before receiving MEDI-546 and a negative urine pregnancy test on days of MEDI-546 administration before receiving MEDI-546);
  • Breastfeeding or lactating women;
  • History of primary immunodeficiency;
  • History of alcohol or drug abuse \< 1 year prior to entry;
  • History of cancer except basal cell carcinoma or in situ carcinoma of the cervix treated with apparent success with curative therapy > 1 year prior to entry;
  • History of active tuberculosis (TB) infection or latent TB infection without completion of an appropriate course of treatment;
  • Newly positive TB skin test (defined as a reaction ≥ 10 mm in diameter if not on systemic medication or ≥ 5 mm if on systemic immunosuppressive medication) without concomitant prophylactic therapy;
  • Elective surgery planned from the time of signing of the through end of study;
  • At screening blood tests (within 28 days before entry), any of the following:

    • (AST) > 2.5 x (ULN), unless due to Myositis
    • Alanine aminotransferase (ALT) > 2.5 x ULN
    • Creatinine > 4.0 mg/dL
    • Creatinine > 4.0 mg/dL
    • Neutrophils \< 1,500/mm3
    • count \< 50,000/mm3;
  • History of any disease, evidence of any current disease (other than scleroderma), any finding upon physical examination, chest x-ray, or any laboratory abnormality that, in the opinion of the investigator or medical monitor, may compromise the safety of the subject in the study or confound the analysis of the study; or
  • Any employee of the research site who is involved with the conduct of the study.
  • History of vasculitis.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
34 participants (actual)

Study arms

  • Other
    1

    MEDI-546

    Drug: MEDI-546

  • Other
    2

    MEDI-546

    Drug: MEDI-546

  • Other
    3

    MEDI-546

    Drug: MEDI-546

  • Other
    4

    MEDI-546

    Drug: MEDI-546

  • Other
    5

    MEDI-546

    Drug: MEDI-546

  • Other
    6

    MEDI-546

    Drug: MEDI-546

  • Other
    7

    MEDI-546

    Drug: MEDI-546

  • Other
    8

    MEDI-546

    Drug: MEDI-546

  • Other
    9

    MEDI-546

    Drug: MEDI-546

Interventions

  • 0.1 mg/kg MEDI-546 as a single IV dose

  • 0.3 mg/kg MEDI-546 as a single IV dose

  • 1.0 mg/kg MEDI-546 as a single IV dose

  • 3.0 mg/kg MEDI-546 as a single IV dose

  • 10.0 mg/kg MEDI-546 as a single IV dose

  • 0.3 mg/kg MEDI-546 as a weekly IV dose x 4 doses

  • 1.0 mg/kg MEDI-546 as a weekly IV dose x 4 doses

  • 5.0 mg/kg MEDI-546 as a weekly IV dose x 4 doses

  • 20.0 mg/kg MEDI-546 as a single IV dose

06

What researchers measure

Primary outcomes

  1. The safety and tolerability of MEDI-546 will be assessed primarily by summarizing treatment-emergent AEs and SAEs.

    Time frame: Study Day 84 for single-dose; Study Day 105 for multi-dose

Secondary outcomes

  1. The secondary endpoints of the study are to assess the PK, IM, and PD of single and multiple IV doses of MEDI-546 in adult subjects with scleroderma.

    Time frame: Study Day 84 for single-dose; Study Day 105 for multi-dose

07

Study locations

11 sites
  • Research Site
    Los Angeles, California 90095, United States
  • Boston University
    Boston, Massachusetts 02118, United States
  • Research Site
    Ann Arbor, Michigan 48106, United States
  • Research Site
    New Brunswick, New Jersey 08903, United States
  • Research Site
    Lake Success, New York 11042, United States
  • Research Site
    Toledo, Ohio 43614, United States
  • Metroplex Clinical Research Center
    Dallas, Texas 75231, United States
  • Research Site
    Houston, Texas 77030, United States
  • University of Utah Medical Center
    Salt Lake City, Utah 84132, United States
  • Research Site
    Salt Lake City, Utah, United States
  • Research Site
    Seattle, Washington 98101, United States
08

References and documents

Publications

  • Goldberg A, Geppert T, Schiopu E, Frech T, Hsu V, Simms RW, Peng SL, Yao Y, Elgeioushi N, Chang L, Wang B, Yoo S. Dose-escalation of human anti-interferon-alpha receptor monoclonal antibody MEDI-546 in subjects with systemic sclerosis: a phase 1, multicenter, open label study. Arthritis Res Ther. 2014 Feb 24;16(1):R57. doi: 10.1186/ar4492. PubMed 24559157 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2009, a primary completion of May 2010 and a completion of Jul 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 29, 2009
First posted
Jun 30, 2009
Start
Sep 2009
Primary completionActual
May 2010
CompletionActual
Jul 2011
Last update
May 8, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00930683
Lead sponsor
MedImmune LLC
Responsible party
Sponsor
First posted
Jun 30, 2009
Start date
Sep 2009
Primary completion
May 2010
Completion
Jul 2011
Last update
May 8, 2012

Study contacts

Stephen Yoo, M.D.
study director · MedImmune LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anifrolumab

Start the discussion